Bleomycin-induced flagellate erythema in a patient with Hodgkin's lymphoma - A case report and review of literature

Publication Date

2015

Journal Title

J Oncol Pharm Pract

Abstract

Bleomycin is a glycopeptide used as a chemotherapeutic agent for lymphomas, germ cell tumors, and pleurodesis of malignant pleural effusions. The pulmonary toxicity of bleomycin is well known while the cutaneous side effects are uncommon and varies from generalized hyperpigmentation, sclerodermoid changes, erythema multiformae, and gangrene to flagellate dermatosis. Here we report a characteristic but rare side effect of flagellate erythema, which developed secondary to bleomycin in a 27-year old woman with Hodgkin's lymphoma after two cycles of treatment with adriamycin, bleomycin, vinblastine, dacarbazine regimen. The rash subsided after discontinuation of bleomycin and treatment with steroids.

Volume Number

22

Issue Number

3

Pages

556-60

Document Type

Article

EPub Date

2015/04/10

Status

Faculty, Northwell Researcher

Facility

School of Medicine; Northwell Health

Primary Department

Hematology/Medical Oncology

PMID

25855241

DOI

10.1177/1078155215580468

Full Text for Zucker SOM at Hofstra/Northwell
For the public and Northwell Health campuses

Share

COinS